Chuck, I understand what is required. Without a partner or a protease/ polymerase inhibitor to throw in the mix- what's required now is a Ph2b HCV oral study with BIT225 + ribavirin on a significant size sample group across different genotypes, or an HCV/HIV co-effected study. IMO
I'm saying that Biotron doesn't have the funds to run BIT225 in this type of trail across big sample groups- They need around 20 million atleast. Therefore more capital must be raised or a partner must be found. However in order to get that partner it looks like they might need to demonstrate the effectiveness of BIT225 in a trail with a bigger sample group. Therefore here is the problem. IMO
HIV results will be interesting, and could be the saving light in terms of a partnership arrangement, and a co-effected study. However judging from the last announcement, they don't seem to be focusing on HIV results as a big turning point for the company. Infact there is very little mention of them...
- Forums
- ASX - By Stock
- in the zone
Chuck, I understand what is required. Without a partner or a...
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 1050263 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 0.019 |
10 | 1774771 | 0.018 |
8 | 927388 | 0.017 |
12 | 3258350 | 0.016 |
7 | 865000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 1000263 | 4 |
0.021 | 555000 | 2 |
0.022 | 997769 | 4 |
0.023 | 1100772 | 2 |
0.024 | 153949 | 2 |
Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |